# GLOW (NCT03462719)

> A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03462719
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions: Ibrutinib; Venetoclax; Chlorambucil; Obinutuzumab; Ibrutinib (as Subsequent Therapy)
- Enrollment: 211
- Primary outcome: Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 127
- Podcasts: 112
- X threads: 77
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=glow-nct03462719

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03462719", "email": "<work email>"}; the inbox owner confirms by the emailed link.